scholarly journals PANCREAS AND ISLET TRANSPLANTATION: CLINICAL INDICATIONS AND CLINICAL RESULTS

Author(s):  
Antonio Secchi

Pancreas transplantation is the more effective cure for type 1 diabetes. Although intensive insulin scheme has been demonstrated to reduce the incidence of diabetes related complication, only pancreas transplantation normalizes glycometabolic control, avoids the risk of severe hypoglycemic events and prevents or in some case ameliorates diabetes related complications. In this review it will be analyzed the impact of pancreas transplantation on diabetes related complication and patient survival. Islet cell transplantation has recently emerged as one the most promising therapeutic approaches to improving glycometabolic control in type 1 diabetic patients and, in many cases, to obtaining insulin independence. Islet cell transplantation requires a relatively short hospital stay and has the advantage of being a relatively noninvasive procedure. The rate of insulin independence 1 year after islet cell transplantation has significantly improved in recent years Data from a recent international Trial confirmed that islet cell transplantation can be potentially a cure for type 1 diabetes. Recent data indicate that insulin independence after islet cell transplantation is associated with an improvement in glucose metabolism and quality of life and with a reduction in hypoglycemic episodes. Islet cell transplantation is still in its initial stages, and many obstacles still need to be overcome. Once clinical islet transplantation has been successfully established, this treatment could even be offered to diabetic patients long before the onset of diabetic complications or to patients with life-threatening hypoglycemic unawareness and brittle diabetes.

2008 ◽  
Vol 16 (2) ◽  
pp. 118-123 ◽  
Author(s):  
Tetsuya Ikemoto ◽  
Hirofumi Noguchi ◽  
Masayuki Shimoda ◽  
Bashoo Naziruddin ◽  
Andrew Jackson ◽  
...  

Diabetes ◽  
2009 ◽  
Vol 58 (10) ◽  
pp. 2267-2276 ◽  
Author(s):  
R. Hilbrands ◽  
V. A.L. Huurman ◽  
P. Gillard ◽  
J. H.L. Velthuis ◽  
M. De Waele ◽  
...  

2017 ◽  
Vol 31 (10) ◽  
pp. e13059 ◽  
Author(s):  
Jessica M. Madrigal ◽  
Rebecca S. Monson ◽  
Betul Hatipoglu ◽  
José Oberholzer ◽  
George T. Kondos ◽  
...  

2005 ◽  
Vol 14 (2-3) ◽  
pp. 77-84 ◽  
Author(s):  
Milene C. Geiger ◽  
Jacqueline V. Ferreira ◽  
Muhammad M. Hafiz ◽  
Tatiana Froud ◽  
David A. Baidal ◽  
...  

This study evaluated the Medtronic MiniMed Continuous Glucose Monitoring System (CGMS) in patients with type 1 diabetes mellitus who underwent successful islet cell transplantation (ICT). The results are compared to standardized self-monitoring (SMBG) of hyperglycemia and mean amplitude of glycemic excursions (MAGE). We studied 19 patients (mean age 40.0 ± 6.7 years) in three groups: six patients post-ICT, seven patients awaiting ICT, and six normal volunteers (controls). Continuous glucose monitoring post-ICT showed remarkable glucose stability compared with patients awaiting ICT. The CGMS group showed modestly higher glucoses (mean 111.5 mg/dl) compared with controls (88 mg/dl). Postprandial glucoses in ICT recipients rarely exceeded 180 mg/dl and were similar to controls. There was no difference in asymptomatic hypoglycemia between control and post-ICT groups. However, a higher incidence of hypoglycemia was observed in patients awaiting ICT. HbA1c and MAGE pre- and post-ICT were 8.3 ± 0.9% and 6 ± 0.3% (p < 0.001) and 109 ± 34 and 41 ± 11 (p < 0.001), respectively. No complications were associated with CGMS. This study suggests ICT significantly improves metabolic control and rate of hypoglycemia when compared with controls and patients awaiting ICT. Similar improvement in metabolic control was observed with SMBG, HbA1c, and MAGE. Although CGMS was not demonstrated to be a superior tool for routine assessment in ICT, it is very helpful in special clinical situations.


Sign in / Sign up

Export Citation Format

Share Document